High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation  by Ming Lim, Andrew Boon et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341S334450
High Donor and Recipient Age Are Not Risk Factors for
Chronic Graft-Versus-Host Disease in the Setting of Anti-
Thymocyte Globulin-Conditioned Hematopoietic Stem
Cell Transplantation
Andrew Boon Ming Lim 1, Jan Storek 2, Ashanka Beligaswatte 3,
Marnie Collins 4, Kate Mason 5, Emily Peizhen Li 6,
Ahsan Chaudhry 7, James A. Russell 2, Andrew Daly 2,
Jeffrey Szer 8, Ian Lewis 9, David Stuart Ritchie 1,10. 1 Clinical
Haematology & Bone Marrow Transplant Service, Royal
Melbourne Hospital, Parkville, Australia; 2 Blood and Bone
Marrow Transplant Program, Tom Baker Cancer Centre/
Foothills Hospital, Calgary, AB, Canada; 3 Department of
Haematology, Royal Adelaide Hospital, Adelaide, Australia;
4 Centre for Biostatistics and Clinical Trials, East Melbourne,
Australia; 5 Royal Melbourne Hospital, Parkville, Victoria,
Australia; 6 Royal Melbourne Hospital, Parkville, Australia;
7 Alberta Blood and Marrow Transplant Program, Calgary, AB,
Canada; 8 Clinical Haematology & BMT Service, Royal
Melbourne Hospital, Parkville, Australia; 9 Haematology, Royal
Adelaide Hospital, Adelaide, SA, Australia; 10 Peter MacCallum
Cancer Centre, East Melbourne, Australia
Rabbit anti-thymocyte globulin (ATG) given with condi-
tioning for allogeneic haematopoietic stem cell trans-
plantation (alloHSCT) is effective in reducing the risk of
chronic graft-versus-host disease (cGVHD). Whether
conventional risk factors for cGVHD apply to ATG-condi-
tioned alloHSCT is not known. Between the years 2004 and
2011, 356 adults (median age 48) from 3 centres received 4.5
mg/kg of Thymoglobulin prior to alloHSCT for haematologic
malignancy (acute leukaemia 58%, chronic myeloid
leukaemia 6%, othermyeloidmalignancy 15%, other lymphoid
malignancy 21%). Donors were unrelated in 64%. Condi-
tioning was myeloablative in 94%. Peripheral blood grafts
were used in 97%. At 3 years, overall survivalwas61.0% (95%CI
55.3-67.3%), cumulative incidence of relapse was 32.6% (95%
CI 26.2-38.5%) and transplant-related mortality was 18.8%
(13.2-24.1%). 342 patients were evaluable for the primary
endpoint of cGVHD requiring systemic immunosuppression
(cGVHD-IS). The cumulative incidence of cGVHD-IS at 3 years
was 37.2% (95% CI 31.1-42.7%). On multivariate analysis, only
prior grade 2-4 aGVHD (HR 3.08, 95% CI 2.10-4.52, P < .001)
was associated with a signiﬁcant increase in risk of cumula-
tive incidence of cGVHD-IS. Recipient age of greater than 40
years was associated with signiﬁcantly less cGVHD-IS (HR
0.66, 95% CI 0.45-0.97, P ¼ .03) in univariate but not multi-
variate analysis. The use of unrelated donors, donor age over
40, female donor/male recipient gender combination and
recipient CMV seropositivity were not associated with
increased cGVHD-IS. There was insufﬁcient power to deter-
mine the effect of graft type (peripheral blood vs bone
marrow) on cGVHD-IS, but the incidence did not appear
higher in peripheral blood graft recipients. In summary, in
this cohort, traditional pre-transplant risk factors for cGVHD
were not predictive. In patients undergoing in vivo T-cell
depleted alloHSCT, novel predictors of cGVHDmaybeneeded.451
Sub-Therapeutic Levels of Oral Tacrolimus Prophylaxis
Prior to Allogeneic Stem Cell Transplant Do Not Predict
the Incidence of Chronic Graft Versus Host Disease
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Texas Transplant Institute, San Antonio, TXChronic graft versus host disease (cGVHD) is a common
complication of allogeneic stem cell transplantation (ASCT).
Tacrolimus prophylaxis has been proven to be instrumental
in the prevention of acute graft versus host disease (aGVHD)
a common precursor to developing cGVHD. Our institution
uses oral tacrolimus prior to ASCT because we perform ASCT
in the outpatient setting and increases ease of administra-
tion. We retrospectively reviewed our experience in 94
consecutive patients (pts) who received ASCT from 10 /10
HLAmatched donors, 47 werematched sibling donors (MSD)
and 47matched unrelated donors (MUD) with a median age
of 50 and 52 respectively. All patients received GVHD
prophylaxis with tacrolimus started orally between day -3
and day -1 at a dose of 0.06mg/kg per day divided twice daily.
Standard short course methotrexate (MTX) was prescribed
for all pts (D1 dose 15mg/m2, D3, 6, and 11 doses at 10mg/
m2). Pts who had sub-therapeutic tacrolimus levels (less
than 5ug/L) on the day of transplant (D0) were compared to
pts who had therapeutic tacrolimus levels (greater than 5ug/
L) for incidence of cGVHD and overall survival. Sixty-eight pts
had tacrolimus levels less than 5ug/L on D0 and 26 pts had
tacrolimus of 5ug/L or greater. Fifty eight of the 94 patients
developed cGVHD and 36 did not develop cGVHD indicating
that there was no signiﬁcant difference in the incidence of
cGVHD in these patients despite the level of tacrolimus on
D0. The 58 pts that developed cGVHD, 42/68 (62%) had
a tacrolimus level less than 5ug/L.The 36 pts that did not
develop cGVHD, 26/68 (38%) had a tacrolimus level less than
5ug/L. With a median follow up of 463 days 54/94 pts (57%)
survive; 40/68 pts (59%) with D0 tacrolimus levels that were
less than 5ug/L, and 14/26 pts (54%) with D0 tacrolimus
levels were greater than or equal to 5ug/L. In conclusion, oral
tacrolimus prophylaxis prior to ASCT at our institution
results in sub-therapeutic levels on the day of transplant in
the majority of patients, however, this does not appear to
impact the overall incidence of cGVHD or survival. As an
incidental ﬁnding, those who developed cGVHD had longer
overall survival versus those who did not develop cGVHD.
This study was limited by its retrospective nature, small size
and single center experience.452
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Donor T cell alloreactivity in hematopoietic stem cell trans-
plantation (HCT) can result in acute graft-versus-host disease
(GVHD) which is a major cause of morbidity and mortality in
HCT. We hypothesized that using T cell receptor repertoire
sequencing, we could identify the most frequent T cell clones
in the gastrointestinal (GI) tract of human patients with
GVHD and subsequent tracking of these disease-associated
